COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer

Tumor Biology

Volumn 31, Issue 1, 2010, Pages 1-7

  Mrena, Johanna ^a   Wiksten, Jan Patrik ^a   Kokkola, Arto ^a   Nordling, Stig ^a   Ristimäki, Ari ^a,b   Haglund, Caj ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

COX 2; Gastric cancer; Multivariate analysis; P53; Survival

Indexed keywords

CYCLIN A; CYCLOOXYGENASE 2; DNA; GELATINASE A; HUR PROTEIN; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; STOMACH CANCER; STOMACH SURGERY;

EID: 77951023237     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-009-0001-4     Document Type: Article

References (39)

1. Kountouras J, Zavos C, Chatzopoulos D. Apoptotic and antiangiogenic strategies in liver and gastrointestinal malignancies. J Surg Oncol. 2005;90(4):249-259
2. Mann JR, DuBois RN. Cyclooxygenase-2 and gastrointestinal cancer. Cancer J. 2004;10(3):145-152
3. Wang D, Dubois RN. Prostaglandins and cancer. Gut. 2006;55 (1):115-122 (Pubitemid 41820645)
4. Oshima H, Oshima M, Inaba K, Taketo MM. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J. 2004;23:1669-1678 (Pubitemid 38579527)
5. Saukkonen K, Tomasetto C, Narko K, Rio MC, Ristimaki A. Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice. Cancer Res. 2003;63 (12):3032-3036 (Pubitemid 36735846)
6. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res. 2000;6(2):519-525 (Pubitemid 30111473)
7. Saukkonen K, Nieminen O, van Rees B, Vilkki S, Harkonen M, Juhola M, et al. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res. 2001;7(7):1923-1931 (Pubitemid 32994826)
8. van Rees BP, Saukkonen K, Ristimaki A, Polkowski W, Tytgat GN, Drillenburg P, et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol. 2002;196 (2):171-179 (Pubitemid 34110898)
9. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57(7):1276-1280 (Pubitemid 27152551)
10. Saukkonen K, Rintahaka J, Sivula A, Buskens CJ, Van Rees BP, Rio MC, et al. Cyclooxygenase-2 and gastric carcinogenesis. Apmis. 2003;111(10):915-925 (Pubitemid 37352608)
11. Li JY, Wang XZ, Chen FL, Yu JP, Luo HS. Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line. World J Gastroenterol. 2003;9(5):915-920 (Pubitemid 36686681)
12. Mrena J, Wiksten JP, Thiel A, Kokkola A, Pohjola L, Lundin J, et al. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res. 2005;11(20):7362-7368 (Pubitemid 41507695)
13. Steele RJ, Lane DP. P53 in cancer: a paradigm for modern management of cancer. Surgeon. 2005;3(3):197-205.
14. Schwartz GK. Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy. J Clin Oncol. 2005;23(20):4499-4508
15. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 2005;65 (10):3980-3985
16. Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res. 2000;257(2):231-237 (Pubitemid 30390473)
17. Baba H, Korenaga D, Kakeji Y, Haraguchi M, Okamura T, Maehara Y. DNA ploidy and its clinical implications in gastric cancer. Surgery. 2002;131(1 Suppl):S63-70. (Pubitemid 34118618)
18. Korenaga D, Okamura T, Saito A, Baba H, Sugimachi K. DNA ploidy is closely linked to tumor invasion, lymph node metastasis, and prognosis in clinical gastric cancer. Cancer. 1988;62(2):309-313
19. Victorzon M, Roberts PJ, Haglund C, von Boguslawsky K, Nordling S. Ki-67 immunoreactivity, ploidy and S-phase fraction as prognostic factors in patients with gastric carcinoma. Oncology. 1996;53(3):182-191 (Pubitemid 26131940)
20. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4 (7):844-847 (Pubitemid 28331029)
21. Mrena J, Wiksten JP, Kokkola A, Nordling S, Haglund C, Ristimaki A. Prognostic significance of cyclin A in gastric cancer. Int J Cancer. 2006;119(8):1897-1901 (Pubitemid 44356848)
22. Mrena J, Wiksten JP, Nordling S, Kokkola A, Ristimaki A, Haglund C. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol. 2006;59(6):618-623 (Pubitemid 43886046)
23. Wiksten JP, Lundin J, Nordling S, Kokkola A, Haglundi C. Comparison of the prognostic value of a panel of tissue tumor markers and established clinicopathological factors in patients with gastric cancer. Anticancer Res. 2008;28 (4C):2279-2287
24. Yonemura Y, Ooyama S, Sugiyama K, Kamata T, De Aretxabala X, Kimura H, et al. Retrospective analysis of the prognostic significance of DNA ploidy patterns and S-phase fraction in gastric carcinoma. Cancer Res. 1990;50(3):509-514 (Pubitemid 20054170)
25. Setala LP, Nordling S, Kosma VM, Lipponen PK, Eskelinen MJ, Hollmen SM, et al. Comparison of DNA ploidy and S-phase fraction with prognostic factors in gastric cancer. Anal Quant Cytol Histol. 1997;19(6):524-532 (Pubitemid 28009389)
26. Abad M, Ciudad J, Rincon MR, Silva I, Paz-Bouza JI, Lopez A, et al. DNA aneuploidy by flow cytometry is an independent prognostic factor in gastric cancer. Anal Cell Pathol. 1998;16 (4):223-231 (Pubitemid 28378278)
27. Russo A, Bazan V, Migliavacca M, Zanna I, Tubiolo C, Tumminello FM, et al. Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma. Clin Cancer Res. 2000;6 (1):178-184 (Pubitemid 30064992)
28. Yasa MH, Bektas A, Yukselen V, Akbulut H, Camci C, Ormeci N. DNA analysis and DNA ploidy in gastric cancer and gastric precancerous lesions. Int J Clin Pract. 2005;59(9):1029-1033 (Pubitemid 43918336)
29. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem. 1999;274(16):10911-10915 (Pubitemid 129528294)
30. Leung WK, To KF, Ng YP, Lee TL, Lau JY, Chan FK, et al. Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer. 2001;84 (3):335-339 (Pubitemid 32154425)
31. Shun CT, Wu MS, Huang SP, Wang HP, Chuang SM, Lin JT. Cyclooxygenase-2 expression correlates with nuclear p53 accumulation in gastric carcinoma. Hepatogastroenterology. 2003;50 (52):988-992 (Pubitemid 36723825)
32. Kawabe A, Shimada Y, Uchida S, Maeda M, Yamasaki S, Kato M, et al. Expression of cyclooxygenase-2 in primary and remnant gastric carcinoma: comparing it with p53 accumulation, Helicobacter pylori infection, and vascular endothelial growth factor expression. J Surg Oncol. 2002;80(2):79-88. (Pubitemid 34569173)
33. Joo YE, Chung IJ, Park YK, Koh YS, Lee JH, Park CH, et al. Expression of cyclooxygenase-2, p53 and Ki-67 in gastric cancer. J Korean Med Sci. 2006;21(5):871-876 (Pubitemid 44611222)
34. Xu L, Zhang SM, Wang YP, Zhao FK, Wu DY, Yan X. Relationship between DNA ploidy, expression of ki-67 antigen and gastric cancer metastasis. World J Gastroenterol. 1999;5 (1):10-11
35. Kunisaki C, Shimada H, Takahashi M, Ookubo K, Moriwaki Y, Akiyama H, et al. Prognostic factors in early gastric cancer. Hepatogastroenterology. 2001;48(37):294-298 (Pubitemid 32226125)
36. Liu XP, Tsushimi K, Tsushimi M, Kawauchi S, Oga A, Furuya T, et al. Expression of p21(WAF1/CIP1) and p53 proteins in gastric carcinoma: its relationships with cell proliferation activity and prognosis. Cancer Lett. 2001;170(2):183-189 (Pubitemid 32709919)
37. Oshima CT, Iriya K, Forones NM. Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer. Neoplasma. 2005;52 (5):420-424
38. Ochiai H, Nakanishi Y, Fukasawa Y, Sato Y, Yoshimura K, Moriya Y, et al. A new formula for predicting liver metastasis in patients with colorectal cancer: immunohistochemical analysis of a large series of 439 surgically resected cases. Oncology. 2008;75 (1-2):32-41.
39. Kim YJ, Kim MA, Im SA, Kim TM, Kim DW, Yang HK, et al. Metastasis-associated protein S100A4 and p53 predict relapse in curatively resected stage III and IV (M0) gastric cancer. Cancer Invest. 2008;26(2):152-158